WeChat Mini Program
Old Version Features

Resistance to MET Inhibition in MET-dependent NSCLC and Therapeutic Activity after Switching from Type I to Type II MET Inhibitors.

Richard Riedel,Jana Fassunke,Hannah L. Tumbrink,Andreas H. Scheel,Carina Heydt,Lena Hieggelke,Matthias Scheffler,Alena Heimsoeth,Lucia Nogova,Sebastian Michels,Jan-Phillip Weber,Rieke N. Fischer,Anna Eisert,Theresa Westphal,Diana Schaufler,Janna Siemanowski,Michaela A. Ihle,Svenja Wagener-Ryczek,Roberta Castiglione,Roberto Pappesch,Jan Rehker, Jessica Juergens,Erich Stoelben,Anne Bunck,Carsten Kobe,Sabine Merkelbach-Bruse,Martin L. Sos,Reinhard Buettner,Juergen Wolf

EUROPEAN JOURNAL OF CANCER（2023）

Cited 16|Views25
Key words
NSCLC,MET exon 14 skipping,MET fusion,MET amplification,Tyrosine kinase inhibitor resistance
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined